Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.65 |
| ▸ | CDK9 | P50750 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 8/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113855 | 0.92 | RAB9A (0.79) | RAB9ASMN1; SMN2TP53NPC1KMT2A | |
| SCHEMBL19500976 | 0.90 | SIRT1 (0.70) | RAB9ASMN1; SMN2NPC1KMT2AMAPT | |
| SCHEMBL4104375 | 0.86 | RAB9A (0.71) | RAB9ASMN1; SMN2TP53NPC1KMT2A | |
| SCHEMBL4111018 | 0.85 | TP53 (0.61) | RAB9ASMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL4112512 | 0.85 | RAB9A (0.69) | RAB9ASMN1; SMN2TP53NPC1KMT2A | |
| SCHEMBL4112392 | 0.85 | RAB9A (0.69) | RAB9ASMN1; SMN2TP53NPC1KMT2A | |
| SCHEMBL4112929 | 0.85 | RAB9A (0.69) | RAB9ASMN1; SMN2TP53TSHRNPC1 | |
| SCHEMBL13185536 | 0.84 | POLB (0.70) | RAB9ASMN1; SMN2TP53NPC1KMT2A | |
| SCHEMBL10264381 | 0.84 | RAB9A (0.69) | RAB9ASMN1; SMN2TP53TSHRNPC1 | |
| SCHEMBL2891493 | 0.84 | SMN1; SMN2 (0.71) | RAB9ASMN1; SMN2TP53EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | claimed |
| EP-1804785-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006049941-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250186411-A1 | Methods of Treating Disorders Associated with Overactivation of IKKB | US GOV VETERANS AFFAIRS (US) | 2025-06-12 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024173283-A1 | MACROENCAPSULATION DEVICES INCLUDING IMMUNOMODULATORY COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| US-20120239365-A1 | Model For Glutamate Racemase inhibitors and Glutamate Racemase Antibacterial Agents | MAHFOUZ TAREK M (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120239365-A1 | Model For Glutamate Racemase inhibitors and Glutamate Racemase Antibacterial Agents | MAHFOUZ TAREK M (US) | 2012-09-20 | — | — | US | disclosed |
| US-8236849-B2 | Model for glutamate racemase inhibitors and glutamate racemase antibacterial agents | OHIO NORTHERN UNIVERSITY (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236849-B2 | Model for glutamate racemase inhibitors and glutamate racemase antibacterial agents | OHIO NORTHERN UNIVERSITY (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100240727-A1 | Model for Glutamate Racemase Inhibitors and Glutamate Racemase Antibacterial Agents | OHIO NORTHERN UNIVERSITY | 2010-09-23 | — | — | US | disclosed |
| US-20100240727-A1 | Model for Glutamate Racemase Inhibitors and Glutamate Racemase Antibacterial Agents | OHIO NORTHERN UNIVERSITY | 2010-09-23 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240727-A1 | Model for Glutamate Racemase Inhibitors and Glutamate Racemase Antibacterial Agents | GRM6, GRM1, GRM2 | RAB9A 2555/4885SMN1; SMN2 4649/4885TP53 4344/4885 |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | RAB9A 815/4885SMN1; SMN2 4056/4885TP53 4802/4885 |
| US-20250186411-A1 | Methods of Treating Disorders Associated with Overactivation of IKKB | NFKBIA, IKBKG, IKBKB | RAB9A 3272/4885SMN1; SMN2 2926/4885TP53 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.